Over the past 16 months, the Trump ad­min­is­tra­tion’s phar­ma tar­iffs have loomed large over the in­dus­try. While the first wave of these levies was sched­uled...

Replimune de­fend­ed the de­sign and re­sults of its piv­otal ad­vanced melanoma tri­al, ar­gu­ing to an FDA ad­vi­so­ry com­mit­tee that its on­colyt­ic virus treat­ment was ben­e­fi­cial...

Re­gen­eron and Sanofi said they are in the ear­ly stages of dis­cussing ar­eas for fur­ther col­lab­o­ra­tion, build­ing on one of the most fruit­ful phar­ma­ceu­ti­cal com­pa­ny...

The Trump ad­min­is­tra­tion’s nom­i­nee to be the next CDC di­rec­tor has won the sup­port of a key Sen­ate com­mit­tee, send­ing her nom­i­na­tion to the full...

Al­ny­lam’s sec­ond-quar­ter earn­ings re­port Thurs­day did lit­tle to as­suage in­vestor con­cerns in what has al­ready been a dif­fi­cult year for the com­pa­ny.

The drug­mak­er low­ered...